LATEST ONCOPRESCRIBE UPDATES
Late Breaking Abstract – ESMO 2024: Addition of XTANDI® to XOFIGO® Significantly Improved Survival in Metastatic Castrate Resistant Prostate cancer
SARCLISA® with VRd Regimen for Transplant Ineligible Newly Diagnosed Multiple Myeloma
IMFINZI® after Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
Superior Outcomes with First Line OPDIVO® versus ADCETRIS® in Advanced Classical Hodgkin Lymphoma
Neoadjuvant Immunotherapy in Early Breast cancer
FDA Approves VYLOY® with Chemotherapy for Biomarker Positive Gastric or GEJ Adenocarcinoma
Liquid Biopsy May Predict Survival in Metastatic Prostate Cancer
Measuring Lymphocyte Count May Predict Response to CAR T-Cell Therapy in Multiple Myeloma